PubMed:32213337 / 2240-2345 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-OGER-BB

    {"project":"LitCovid-OGER-BB","denotations":[{"id":"T54","span":{"begin":5,"end":15},"obj":"SP_7"},{"id":"T55","span":{"begin":27,"end":37},"obj":"SP_7"},{"id":"T56","span":{"begin":27,"end":41},"obj":"PG_11"},{"id":"T57","span":{"begin":42,"end":45},"obj":"GO:0071735"},{"id":"T58","span":{"begin":69,"end":74},"obj":"NCBITaxon:10239"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"Anti-SARS-CoV-2-NP or anti-SARS-CoV-2-RBD IgG levels correlated with virus neutralisation titre (R2\u003e0·9)."}

    LitCovid-OGER

    {"project":"LitCovid-OGER","denotations":[{"id":"T23","span":{"begin":69,"end":74},"obj":"GO:0019012"},{"id":"T7","span":{"begin":5,"end":9},"obj":"PR:000014459"},{"id":"T8","span":{"begin":27,"end":31},"obj":"PR:000014459"}],"namespaces":[{"prefix":"PR","uri":"http://purl.obolibrary.org/obo/PR_"},{"prefix":"UBERON","uri":"http://purl.obolibrary.org/obo/UBERON_"}],"text":"Anti-SARS-CoV-2-NP or anti-SARS-CoV-2-RBD IgG levels correlated with virus neutralisation titre (R2\u003e0·9)."}

    LitCovid-sentences-v1

    {"project":"LitCovid-sentences-v1","denotations":[{"id":"TextSentencer_T21","span":{"begin":0,"end":105},"obj":"Sentence"}],"text":"Anti-SARS-CoV-2-NP or anti-SARS-CoV-2-RBD IgG levels correlated with virus neutralisation titre (R2\u003e0·9)."}

    LitCovid-TimeML

    {"project":"LitCovid-TimeML","denotations":[{"id":"tok459","span":{"begin":0,"end":5},"obj":"NNP"},{"id":"tok460","span":{"begin":5,"end":14},"obj":"NNP"},{"id":"tok461","span":{"begin":14,"end":15},"obj":"CD"},{"id":"tok462","span":{"begin":15,"end":16},"obj":":"},{"id":"tok463","span":{"begin":16,"end":18},"obj":"NNP"},{"id":"tok464","span":{"begin":19,"end":21},"obj":"CC"},{"id":"tok465","span":{"begin":22,"end":27},"obj":"NN"},{"id":"tok466","span":{"begin":27,"end":36},"obj":"NNP"},{"id":"tok467","span":{"begin":36,"end":37},"obj":"CD"},{"id":"tok468","span":{"begin":37,"end":38},"obj":":"},{"id":"tok469","span":{"begin":38,"end":41},"obj":"NNP"},{"id":"tok470","span":{"begin":42,"end":45},"obj":"NNP"},{"id":"tok471","span":{"begin":46,"end":52},"obj":"NNS"},{"id":"tok472","span":{"begin":53,"end":63},"obj":"JJ"},{"id":"tok473","span":{"begin":64,"end":68},"obj":"IN"},{"id":"tok474","span":{"begin":69,"end":74},"obj":"NN"},{"id":"tok475","span":{"begin":75,"end":89},"obj":"NN"},{"id":"tok476","span":{"begin":90,"end":95},"obj":"NN"},{"id":"tok477","span":{"begin":96,"end":97},"obj":"("},{"id":"tok478","span":{"begin":97,"end":98},"obj":"NN"},{"id":"tok479","span":{"begin":98,"end":99},"obj":"CD"},{"id":"tok480","span":{"begin":99,"end":100},"obj":"NN"},{"id":"tok481","span":{"begin":100,"end":101},"obj":"CD"},{"id":"tok482","span":{"begin":101,"end":102},"obj":"NN"},{"id":"tok483","span":{"begin":102,"end":103},"obj":"CD"},{"id":"tok484","span":{"begin":103,"end":104},"obj":")"},{"id":"tok485","span":{"begin":104,"end":105},"obj":"."}],"text":"Anti-SARS-CoV-2-NP or anti-SARS-CoV-2-RBD IgG levels correlated with virus neutralisation titre (R2\u003e0·9)."}

    LitCovid-PD-MONDO-v1

    {"project":"LitCovid-PD-MONDO-v1","denotations":[{"id":"T16","span":{"begin":5,"end":13},"obj":"Disease"},{"id":"T17","span":{"begin":27,"end":35},"obj":"Disease"},{"id":"T18","span":{"begin":97,"end":101},"obj":"Disease"},{"id":"T19","span":{"begin":97,"end":99},"obj":"Disease"}],"attributes":[{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0015436"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0019903"}],"text":"Anti-SARS-CoV-2-NP or anti-SARS-CoV-2-RBD IgG levels correlated with virus neutralisation titre (R2\u003e0·9)."}

    LitCovid-PD-FMA-UBERON-v1

    {"project":"LitCovid-PD-FMA-UBERON-v1","denotations":[{"id":"T24","span":{"begin":42,"end":45},"obj":"Body_part"}],"attributes":[{"id":"A24","pred":"fma_id","subj":"T24","obj":"http://purl.org/sig/ont/fma/fma62872"}],"text":"Anti-SARS-CoV-2-NP or anti-SARS-CoV-2-RBD IgG levels correlated with virus neutralisation titre (R2\u003e0·9)."}